Products & Technologies

Leveraging and enhancing the power of tumor infiltrating lymphocytes (TILs) to treat, and potentially cure, all solid tumors.

Learn More

About

Lion Biotechnologies is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs).

Learn More

Clinical Trials

Now recruiting: Phase 2 study of LN-144 followed by IL-2 in the treatment of refractory metastatic melanoma.

Learn More

Investor Relations

Lion Biotechnologies, Inc.

Symbol NASDAQ: LBIO
Price
Change
Volume
Day Low/High
52 Week Low/High